Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

@article{Verbeeck2008PharmacokineticsAD,
  title={Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction},
  author={Roger K. Verbeeck},
  journal={European Journal of Clinical Pharmacology},
  year={2008},
  volume={64},
  pages={1147-1161}
}
  • R. Verbeeck
  • Published 2008
  • Medicine, Biology
  • European Journal of Clinical Pharmacology
The liver plays a central role in the pharmacokinetics of the majority of drugs. Liver dysfunction may not only reduce the blood/plasma clearance of drugs eliminated by hepatic metabolism or biliary excretion, it can also affect plasma protein binding, which in turn could influence the processes of distribution and elimination. Portal-systemic shunting, which is common in advanced liver cirrhosis, may substantially decrease the presystemic elimination (i.e., first-pass effect) of high… 
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
TLDR
It is shown that renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites, and a re-evaluation of markers of renal function may be required, even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed.
Analgesics in Patients with Hepatic Impairment
TLDR
All opioid drugs can precipitate or aggravate hepatic encephalopathy in patients with severe liver disease, thus requiring cautious use and careful monitoring.
Drug-related problems and dosage adjustment in patients with liver disease
TLDR
Potential drug-cost savings as a result of mere dose adjustment in patients with liver cirrhosis was minor, but considerable when taking into account hospitalizations due to preventable ADRs caused by IDDs.
Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments
TLDR
Although it is important to consider these potential alterations and their effects on specific anti-infectives, many lack data to constitute specific dosing adjustments, making it important to monitor patients for effectiveness and toxicities of therapy.
Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
TLDR
The treatment possibilities in HCV patients with hepatic and renal impairment are described and grazoprevir plus elbasvir is the preferred DAA regimen in patients with renal impairment as data are pending for sofosbuvir patients with GFR <30 mL/min (as for ledipasvir and velpatasvir).
Pharmacokinetic drug interactions in liver disease: An update.
TLDR
It is indicated that the magnitude of metabolic drug-drug interactions in patients with liver disease cannot be inferred from studies in healthy subjects, and both the effects and the plasma concentration of the induced drug should be strictly monitored.
Pharmacokinetic Changes in Liver Failure and Impact on Drug Therapy
TLDR
In order to better predict the impact of hepatic dysfunction on medication pharmacokinetics, it is important to understand the factors affecting hepatic metabolism.
Pharmacokinetics of Antidepressants in Patients with Hepatic Impairment
Appropriate use of antidepressant in patients with hepatic impairment requires careful consideration of how the hepatic illness may affect pharmacokinetics. This review aims to analyze
Management of Pharmacologic Adverse Effects in Advanced Liver Disease
TLDR
Although the hepatic toxicity of some frequently used drugs, such as acetaminophen, is well known, many health care professionals are unaware or not fully aware of the deleterious effects that other drugs can have on patients with advanced liver injury.
A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
TLDR
Predictions of the effects of liver cirrhosis on drug clearance are of potential value in the design of clinical studies during drug development and, clinically, in the assessment of likely dosage adjustment.
...
...

References

SHOWING 1-10 OF 132 REFERENCES
Hepatic First-pass Metabolism in Liver Disease
TLDR
Several studies show relative preservation of systemic clearance in the face of substantial increases in bioavailability, suggesting that the hepatic arterial blood supply of the liver is an important determinant of systems clearance in cirrhotic patients.
Protein Binding and Kinetics of Drugs in Liver Diseases
  • T. Blaschke
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1977
TLDR
The efficiency with which a drug is metabolised by the liver, the extent of binding to blood constituents, and the aetiology and stage of the hepatic disorder are each important in determining whether significant alterations in drug disposition will occur.
Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver Disease
TLDR
Clinical data are substantially consistent with the latter 2 theories, which regard the decreased permeability of the capillarised sinusoid as the critical feature in cirrhosis, and further work is required to determine the applicability of each of these theories.
Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide
TLDR
Fu “excretion rate — response” curves showed diminished tubular sensitivity to Fu in cirrhosis, and there was a significant reduction in urine sodium and volume, whereas potassium excretion remained unchanged.
Pharmacokinetics of Opioids in Liver Disease
TLDR
Although glucuronidation is thought to be less affected in liver cirrhosis, the clearance of morphine was found to be decreased and oral bioavailability increased, and the disposition of a few opioids, such as fentanyl, sufent anil and remifentanil, appears to be unaffected in liver disease.
Cardiovascular Drug Therapy in Patients with Hepatic Diseases and Patients with Congestive Heart Failure
TLDR
This article provides guidance for dosing cardiovascular drugs in cirrhotic and heart failure patients based on available research data and suggests that further research is needed in congestive heart failure to better elucidate safe prescribing patterns.
The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.
TLDR
In all cases, a reduction in drug metabolizing enzyme activities in liver cirrhosis contributes to decreased clearance of drugs seen in patients with liver abnormalities, especially in patientsWith severe liver disease.
Pharmacokinetics of Midazolam Following Intravenous and Oral Administration in Patients with Chronic Liver Disease and in Healthy Subjects
TLDR
On a pharmacokinetic basis a reduced dosage of midazolam to patients with advanced cirrhosis of the liver is recommended, and on a hypnotic basis the hypnotic effects of midAZolam were similar in both groups.
Antiarrhythmics: elimination and dosage considerations in hepatic impairment.
  • U. Klotz
  • Medicine, Biology
    Clinical pharmacokinetics
  • 2007
TLDR
In conclusion, hepatic impairment decreases the elimination of many antiarrhythmics to such an extent that dosage reductions are highly recommended in such populations, especially in patients with cirrhosis.
Pharmacokinetics of Metoprolol in Patients with Hepatic Cirrhosis
TLDR
Impaired liver function had no effect on the volume of distribution of metoprolol and the half-life of the drug was related to serum bilirubin and total body clearance was weakly but linearly related to galactose clearance.
...
...